Recently the ZoBio team made an important contribution to a drug discovery project for our client Mirati Therapeutics that we are particularly proud of and has had significant impact [1]. This work describes a program to develop inhibitors of the epigenetic target PRMT5 with the potential to …
Eurostars DiscoveRNA Project Awarded!
RNA as a potential drug target is currently gaining a lot of interest, but the right technologies are not all in place to successfully pursue them. ZoBio and its partner ETH Zurich have been awarded with a €1.2 million EUREKA Eurostars grant, to establish an automated pipeline enabling…
Remarkable NMR Achievement in Collaboration with ESSA Pharma
The androgen receptor (AR) pathway drives most metastatic, castration-resistant prostate cancers (mCRPC). Anti-androgen resistance mechanisms include AR gene amplification, C-terminal ligand-binding domain (LBD) mutations and expression of constitutively-active truncated AR splice variants lacking…
Biacore 8K+ in the House!
Working on challenging projects requires access to state-of-the-art equipment.
Over the past 16 years ZoBio has incorporated multiple analytical technologies into its workflow to better enable us to tackle the challenging projects our clients task us with. In addition to NMR, SPR technology has taken its place at the core of what we do due to the ability to impact drug discovery programs…